BEIJING, Feb. 8 (Xinhua) — Silicon Valley biotech start-up GenapSys is in contact with Chinese health authorities to combat the outbreak of new coronavirus infection pneumonia. A spokesman for GenapSys said that on January 29th the CDC approached the company about helping to fight the outbreak and that “discussions with the CDC are at an early stage on how to fight the outbreak more effectively.”
Pictured: GenapSys gene sequencer the size of an iPad
GenapSys is just one percent the size of an iPad compared to the traditional gene sequencers currently on the market. It can be easily deployed at hospitals, airports and bus stops to quickly sequence virus samples and “perfectly fit” for emergencies.
Genetic sequencing can provide a complete understanding of the virus, helping public health officials and researchers track the virus’s evolution, develop vaccines, and develop strategies to control the spread of the epidemic.
Picture: Illumina Gene Sequencer
Genetic sequencing is currently done mainly in large laboratories, which use Illumina’s sequencers, which cost close to $1 million each. The GenapSys sequencer sells for $10,000 in the U.S. and will sell for similar prices in other countries. (Author/Frost Leaf)